Reliable, Broad Assessment of Active Rejection
Cells from a transplanted organ release donor-derived cell-free DNA (dd-cfDNA) upon graft injury or death, which can indicate active rejection. To distinguish between dd-cfDNA and recipient DNA, Prospera utilizes more than 13,000 single nucleotide polymorphisms, or SNPs. Prospera leverages a proven and established methodology to assess the patient’s blood for antibody-mediated rejection (ABMR), T-cell mediated rejection (TCMR), and mixed rejection.
Clinically validated to assess active rejection with high accuracy
The current standard of care for the assessment of allograft injury and rejection in kidney recipients is the standard biopsy, which is invasive as well as risky and costly in many cases. Natera offers a new technology for a more precise and non-invasive method of testing for injury and rejection. The Prospera Transplant Assessment test can measure levels of dd-cfDNA in order to help physicians identify rejection events earlier, avoid unnecessary biopsies, and ultimately improve care for transplant patients.
Advantages of Prospera
More sensitive and specific to evidence of clinical and subclinical active rejection than serum creatinine¹
Simple blood test that is less invasive than biopsy; no donor genotyping required
Suitable for most renal allograft patients across ethnicities
Up to 5x reduction in variability than that of a competitive dd-cfDNA assay², ³
¹ Sigdel et al. J. Clin. Med. 2019
² Altug, et al. Transplantation, 2019
³ Grskovic, et al. J Mol Diagn. 2016;18(6):890-902
How does Prospera work?
Natera’s technology can measure the levels of dd-cfDNA shed from the donor organ which may be an indication of the potential of organ injury or rejection.
1. Recipient Blood
Test mix of donor & recipient blood cell-free DNA. Donor genotyping not required.
2. Ship Specimen
Send a blood sample
3. Process Specimen
Natera distinguishes between donor & recipient DNA using SNPs - the 1% of our DNA that akes us unique